Print

Value returns to The Medicines Company with court decision

Date August 04, 2010

The Medicines Company got yet another reprieve on Angiomax as a court yesterday extended the life of the much-disputed US patent on the anti-coagulant. The district court’s insistence that the US Patent and Trademark Office (USPTO) is misinterpreting deadlines for filing patent term extensions suggests that this legal wrangle is likely to continue, extending the current patent protections and boosting TMC’s bottom line (Court ruling sparks share rally for The Medicines Company, March 17, 2010).

TMC shares surged 34% to $12.47 on news of the decision to an 18-month high, demonstrating how important the Angiomax patent is to the New Jersey company’s fortunes. With Angiomax constituting nearly all of its sales this year and comparatively small forecasts for its remaining marketed and pipeline products, every day TMC can extend the Angiomax patent past the currently estimated expiration of November 23 is welcome extra revenue.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2014 EP Vantage Ltd